A peptide is identified to disrupt the USP25‐SHLD2 interaction, impair NHEJ pathway, and increase sensitivity to chemotherapy in PDX model, thereby proposing a potential therapeutic strategy for cancer therapy. Here, SHLD2 is linked to cancer.